https://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-hits-52-week-high-at-338-73-61b58ce637bf150dPharma Surgeen2026-06-24T14:20:19.000ZWest Pharmaceutical Services stock hits 52-week high at $338.73https://www.pharmaradar360.com/article/news-pharmaceutical-giant-plans-more-than-1-billion-expansion-in-jacksonville-fl-b6b5ca31dd14d7b6Pharma Surgeen2026-06-24T14:19:51.000ZNews | Pharmaceutical giant plans more than $1 billion expansion in Jacksonville, Floridahttps://www.pharmaradar360.com/article/at-bio-a-glimpse-behind-lilly-and-chai-s-partnership-cef7fd9e504fd687Pharma Surgeen2026-06-24T14:14:53.000ZAt BIO, a glimpse behind Lilly and Chai’s partnershiphttps://www.pharmaradar360.com/article/drug-discovery-technologies-market-2026-2030-in-f8be93385467bd32Pharma Surgeen2026-06-24T14:09:42.000ZDrug Discovery Technologies Market 2026-2030 | Inhttps://www.pharmaradar360.com/article/london-biotech-biz-to-buy-cancer-focused-us-co-for-17m-5bd47ad64474c6b6Pharma Surgeen2026-06-24T14:09:00.000ZLondon Biotech Biz To Buy Cancer-Focused US Co. For £17Mhttps://www.pharmaradar360.com/article/6-biotech-stocks-that-delivered-stunning-gains-inbx-700-pvla-500-mbx-300-absi-20-8d75422a47ff2d5aPharma Surgeen2026-06-24T14:04:00.000Z6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & Morehttps://www.pharmaradar360.com/article/novartis-targets-undruggable-cancers-with-1-9bn-antares-therapeutics-deal-3b1a378e87b0d871Pharma Surgeen2026-06-24T14:03:00.000ZNovartis targets undruggable cancers with $1.9bn Antares Therapeutics dealhttps://www.pharmaradar360.com/article/endpoints-100-survey-biotech-ceos-predict-mfn-maneuvering-and-offer-a-few-ideas-7819886b423379a4Pharma Surgeen2026-06-24T14:00:00.000ZEndpoints 100 survey: Biotech CEOs predict MFN maneuvering and offer a few ideas for the FDAhttps://www.pharmaradar360.com/article/the-brown-capital-management-small-company-fund-bets-on-krystal-biotech-krys-for-60dbac6a0e45bdc5Pharma Surgeen2026-06-24T13:55:13.000ZThe Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Streamhttps://www.pharmaradar360.com/article/lundbeck-s-new-r-d-boss-welcomes-promotion-0d147d657f37ffb7Pharma Surgeen2026-06-24T13:15:57.000ZLundbeck's new R&D boss welcomes promotionhttps://www.pharmaradar360.com/article/jules-monneret-had-the-opportunity-to-explore-pharmaceutical-randd-at-servier-fr-29ac8df4c5a81261Pharma Surgeen2026-06-24T13:06:05.000ZJules Monneret: Had the Opportunity to Explore Pharmaceutical RandD at Servier Francehttps://www.pharmaradar360.com/article/abbott-pens-blood-based-alzheimer-s-testing-pact-with-alzpath-75f52fcd51abc0fdPharma Surgeen2026-06-24T13:02:46.000ZAbbott pens blood-based Alzheimer's testing pact with ALZpathhttps://www.pharmaradar360.com/article/roundtable-patient-services-leaders-on-the-pressures-shaping-hubs-in-2026-636d31aedc68b6f7Pharma Surgeen2026-06-24T12:57:09.000ZRoundtable: Patient Services Leaders on the Pressures Shaping Hubs in 2026https://www.pharmaradar360.com/article/osanni-bio-raises-190-million-series-b-to-advance-therapeutics-platform-8e795dc3dd934bcbPharma Surgeen2026-06-24T12:56:15.000ZOsanni Bio raises $190 million Series B to advance therapeutics platformhttps://www.pharmaradar360.com/article/lilly-completes-acquisition-of-centessa-pharmaceuticals-to-advance-treatments-fo-05025734047b39ebPharma Surgeen2026-06-24T12:45:00.000ZLilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disordershttps://www.pharmaradar360.com/article/medicines-storage-needs-to-change-with-the-climate-f04ef057fea4d8d0Pharma Surgeen2026-06-24T12:41:05.000ZMedicines storage needs to change with the climatehttps://www.pharmaradar360.com/article/4127dbd62a899b14Pharma Surgeen2026-06-24T12:36:33.000ZΑΝΑΚΟΙΝΩΣΗ – ΔΙΑΚΟΠΗ ΗΛΕΚΤΡΟΝΙΚΩΝ ΥΠΗΡΕΣΙΩΝhttps://www.pharmaradar360.com/article/finetech-debuts-fully-automatic-liquid-capsule-filling-machine-at-cphi-china-202-2e6f60087dbb9956Pharma Surgeen2026-06-24T12:36:12.000ZFinetech Debuts Fully Automatic Liquid Capsule Filling Machine at CPhI China 2026 in Shanghaihttps://www.pharmaradar360.com/article/legionellosis-in-residents-of-england-and-wales-2025-ddbdab6f2a833e23Pharma Surgeen2026-06-24T12:29:15.000ZLegionellosis in residents of England and Wales: 2025https://www.pharmaradar360.com/article/martha-s-rule-extended-to-all-maternity-services-9101c6b1a3e571c1Pharma Surgeen2026-06-24T12:17:49.000ZMartha's Rule extended to all maternity serviceshttps://www.pharmaradar360.com/article/guidance-covid-19-test-validation-approved-products-af58b94cdba0a949Pharma Surgeen2026-06-24T12:16:57.000ZGuidance: COVID-19 test validation approved productshttps://www.pharmaradar360.com/article/notice-register-of-authorised-online-sellers-of-medicines-in-northern-ireland-a31b13f8e8d05b4ePharma Surgeen2026-06-24T12:01:27.000ZNotice: Register of authorised online sellers of medicines in Northern Irelandhttps://www.pharmaradar360.com/article/gsk-announces-commencement-of-tender-offer-to-acquire-nuvalent-inc-ef6efcc7043085caPharma Surgeen2026-06-24T12:00:00.000ZGSK announces commencement of tender offer to acquire Nuvalent, Inc.https://www.pharmaradar360.com/article/biotech-visionary-is-skeptical-about-ai-s-impact-on-medical-innovation-03981e96decca9d0Pharma Surgeen2026-06-24T12:00:00.000ZBiotech Visionary Is Skeptical About AI’s Impact on Medical Innovationhttps://www.pharmaradar360.com/article/botox-cosmetic-onabotulinumtoxina-introduces-the-confidence-collective-s-entrepr-1eef10263600357ePharma Surgeen2026-06-24T12:00:00.000ZBOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026https://www.pharmaradar360.com/article/insulet-hires-convatec-eli-lilly-alum-as-new-r-d-chief-56e5a2f5e7f0f4c7Pharma Surgeen2026-06-24T11:57:28.000ZInsulet hires Convatec, Eli Lilly alum as new R&D chiefhttps://www.pharmaradar360.com/article/after-apogee-3-more-biotech-buyout-targets-wall-street-can-t-stop-watching-4570c983a1db1d6fPharma Surgeen2026-06-24T11:55:10.000ZAfter Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watchinghttps://www.pharmaradar360.com/article/clostridioides-difficile-infection-how-to-deal-with-the-problem-160391dd74331fafPharma Surgeen2026-06-24T11:49:37.000ZClostridioides difficile infection: how to deal with the problemhttps://www.pharmaradar360.com/article/eli-lilly-reunites-with-abbisko-in-1-9b-multiple-target-r-d-pact-12ac490e136f184aPharma Surgeen2026-06-24T11:47:46.000ZEli Lilly reunites with Abbisko in $1.9B, multiple target R&D pacthttps://www.pharmaradar360.com/article/unlocking-the-sustainability-data-inside-biotech-operations-53df70c1eabc86b1Pharma Surgeen2026-06-24T11:46:13.000ZUnlocking the Sustainability Data Inside Biotech Operationshttps://www.pharmaradar360.com/article/bio-2026-us-needs-to-dodge-china-s-inescapable-dependencies-to-protect-biotech-641507cd70ca8b4fPharma Surgeen2026-06-24T11:23:31.000ZBIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotechhttps://www.pharmaradar360.com/article/helus-pharma-provides-update-on-approach-phase-3-trial-enrollment-progress-8a40d76634fb17b2Pharma Surgeen2026-06-24T11:23:05.000ZHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progresshttps://www.pharmaradar360.com/article/drug-compounding-was-meant-for-individuals-empower-pharmacy-serves-70k-a-week-c7cc65d12a4e7763Pharma Surgeen2026-06-24T11:10:59.000ZDrug compounding was meant for individuals. Empower Pharmacy serves 70K a week.https://www.pharmaradar360.com/article/ockenden-review-into-maternity-services-at-nottingham-university-hospitals-nhs-t-36fe922f80f82f6dPharma Surgeen2026-06-24T11:06:27.000ZOckenden review into maternity services at Nottingham University Hospitals NHS Trust: final reporthttps://www.pharmaradar360.com/article/ophthalmology-venture-grabs-investors-attention-raises-330-million-da66c414c437d06cPharma Surgeen2026-06-24T11:04:40.000ZOphthalmology venture grabs investors’ attention, raises $330 millionhttps://www.pharmaradar360.com/article/veraxa-adds-60-more-lab-space-in-heidelberg-for-cancer-drug-work-a5cd98c6364b3f8dPharma Surgeen2026-06-24T11:00:00.000ZVERAXA adds 60% more lab space in Heidelberg for cancer drug workhttps://www.pharmaradar360.com/article/fda-gives-calcimedica-no-comments-on-auxora-safety-review-b825359f44b822efPharma Surgeen2026-06-24T11:00:00.000ZFDA gives CalciMedica no comments on Auxora safety reviewhttps://www.pharmaradar360.com/article/ollin-hauls-in-330m-to-enlist-vabysmo-challenger-in-phase-3-eye-disease-gauntlet-d915e0de9d7fa235Pharma Surgeen2026-06-24T11:00:00.000ZOllin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlethttps://www.pharmaradar360.com/article/what-does-practical-sustainability-in-api-manufacturing-really-look-like-03e54795f2fc6509Pharma Surgeen2026-06-24T10:59:30.000ZWhat does practical sustainability in API manufacturing really look like?https://www.pharmaradar360.com/article/oura-and-lilly-join-forces-to-harmonise-drug-wearable-obesity-care-a8b25e8ea8fe1a57Pharma Surgeen2026-06-24T10:47:40.000ZŌURA and Lilly join forces to harmonise drug-wearable obesity carehttps://www.pharmaradar360.com/article/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedot-e83dd7d232ad217aPharma Surgeen2026-06-24T10:45:00.000ZEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-rises-wednesday-outperforms-competitors-99a03b79f1224b97Pharma Surgeen2026-06-24T10:32:00.000ZSun Pharmaceutical Industries rises Wednesday, outperforms competitorshttps://www.pharmaradar360.com/article/how-ups-is-adressing-pharmaceutical-procurement-challenges-1b0816db0394ea17Pharma Surgeen2026-06-24T10:08:07.000ZHow UPS is Adressing pharmaceutical Procurement Challengeshttps://www.pharmaradar360.com/article/helus-pharma-says-phase-3-depression-trial-is-86-enrolled-7486167422b33d49Pharma Surgeen2026-06-24T10:00:00.000ZHelus Pharma says Phase 3 depression trial is 86% enrolledhttps://www.pharmaradar360.com/article/helus-pharma-provides-update-on-approach-phase-3-trial-enrollment-progress-c5e27cbbb7c655e5Pharma Surgeen2026-06-24T10:00:00.000ZHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progresshttps://www.pharmaradar360.com/article/the-new-drug-compound-that-could-treat-measles-outbreaks-and-other-viruses-9253f0753bedd2a9Pharma Surgeen2026-06-24T09:25:02.000ZThe new drug compound that could treat measles outbreaks – and other viruseshttps://www.pharmaradar360.com/article/corxel-s-oral-obesity-drug-clears-phase-ii-test-e7b35f5ebfeb9d53Pharma Surgeen2026-06-24T09:20:46.000ZCORXEL’s oral obesity drug clears Phase II testhttps://www.pharmaradar360.com/article/sangamo-files-for-bankruptcy-as-lilly-and-astellas-target-assets-22193f6d97baac4cPharma Surgeen2026-06-24T09:08:55.000ZSangamo files for bankruptcy as Lilly and Astellas target assetshttps://www.pharmaradar360.com/article/former-vertex-gsk-exec-launches-science-first-pet-nutrition-company-53f3d6ffcacd61d5Pharma Surgeen2026-06-24T09:08:00.000ZFormer Vertex, GSK exec launches science-first pet nutrition companyhttps://www.pharmaradar360.com/article/early-biomarkers-as-predictors-of-nephrology-trial-trajectory-c87dcbd28d59b554Pharma Surgeen2026-06-24T08:53:01.000ZEarly Biomarkers as Predictors of Nephrology Trial Trajectoryhttps://www.pharmaradar360.com/article/the-things-to-think-about-before-taking-your-biotech-company-public-3472dda2cc6cc70fPharma Surgeen2026-06-24T07:50:03.000ZThe Things to Think About Before Taking Your Biotech Company Publichttps://www.pharmaradar360.com/article/pharmaceutical-omega-3-api-market-to-reach-usd-2-3-billion-by-2036-as-prescripti-83447f70072dadafPharma Surgeen2026-06-24T07:02:01.000ZPharmaceutical Omega-3 API Market to Reach USD 2.3 Billion by 2036 as Prescription Cardiovascular Therapies Drive Demand for High-Purity EPA APIs, FMIhttps://www.pharmaradar360.com/article/coiled-therapeutics-appoints-biotech-veteran-craig-tooman-to-board-1fc0eabf27f963a5Pharma Surgeen2026-06-24T06:56:00.000ZCoiled Therapeutics appoints biotech veteran Craig Tooman to boardhttps://www.pharmaradar360.com/article/revolution-medicines-opens-rasolute-305-trial-of-zoldonrasib-in-ras-g12d-pancrea-89d1548a6996ac96Pharma Surgeen2026-06-24T06:52:59.000ZRevolution Medicines Opens RASolute 305 Trial of Zoldonrasib in RAS G12D Pancreatic Cancerhttps://www.pharmaradar360.com/article/when-your-sponsor-gets-acquired-mid-trial-your-site-pays-the-operational-price-5d99f0b797d5c58fPharma Surgeen2026-06-24T06:52:59.000ZWhen Your Sponsor Gets Acquired Mid-Trial, Your Site Pays the Operational Pricehttps://www.pharmaradar360.com/article/first-aid-socialists-target-biotech-sweetener-64428c78af11f7e3Pharma Surgeen2026-06-24T06:52:03.000ZFIRST AID: Socialists target biotech sweetenerhttps://www.pharmaradar360.com/article/mckesson-selects-moore-oklahoma-for-179-million-state-of-the-art-pharmaceutical-fd5cf5e31cb48e12Pharma Surgeen2026-06-24T06:35:00.000ZMcKesson Selects Moore, Oklahoma for $179 Million State-of-the-Art Pharmaceutical Distribution Centerhttps://www.pharmaradar360.com/article/bio-usa-korean-biotech-has-innovation-now-it-needs-capital-13c2f930339dcaeaPharma Surgeen2026-06-24T06:30:11.000Z[Bio USA] Korean biotech has innovation. Now it needs capitalhttps://www.pharmaradar360.com/article/unixell-biotechnology-secures-fda-ind-clearance-for-ux-da003-achieving-china-u-s-6074a2411a1b8ca8Pharma Surgeen2026-06-24T06:25:22.000ZUniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapyhttps://www.pharmaradar360.com/article/pharma-ai-summer-update-preview-drive-the-future-of-pharmaceutical-intelligence-216a46d92fa7b3cfPharma Surgeen2026-06-24T05:23:42.000ZPharma.AI Summer Update Preview: Drive the future of pharmaceutical intelligencehttps://www.pharmaradar360.com/article/araris-biotech-ag-and-taiho-oncology-announce-dosing-of-first-patient-in-phase-1-524924865415451bPharma Surgeen2026-06-24T05:06:30.000ZAraris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphomahttps://www.pharmaradar360.com/article/reuters-health-news-summary-830b6b2e738c63e2Pharma Surgeen2026-06-24T04:59:21.000ZReuters Health News Summaryhttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-wst-pricey-as-glp-1-demand-lifts-expectations-c298653e5750d138Pharma Surgeen2026-06-24T04:57:22.000ZIs West Pharmaceutical Services (WST) Pricey As GLP 1 Demand Lifts Expectations?https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-stock-after-94-one-year-surge-is-the-price-j-3a182297afe4369ePharma Surgeen2026-06-24T03:28:00.000ZTeva Pharmaceutical Industries (TEVA) Stock After 94% One-Year Surge Is The Price Justifiedhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-seeks-10m-capital-injection-0d20182ec834882bPharma Surgeen2026-06-24T03:28:00.000ZRecce Pharmaceuticals seeks $10m capital injectionhttps://www.pharmaradar360.com/article/fda-backs-aft-s-injectable-iron-into-phase-3-study-as-company-targets-global-sca-76d8d198932e6eb3Pharma Surgeen2026-06-24T02:58:29.000ZFDA backs AFT’s injectable iron into Phase 3 study as company targets global scalehttps://www.pharmaradar360.com/article/pharmac-introduces-a-new-vision-and-strategic-priorities-640e013d777e6b11Pharma Surgeen2026-06-24T02:00:00.000ZPharmac introduces a new vision and strategic prioritieshttps://www.pharmaradar360.com/article/pharmac-funds-another-adhd-medicine-to-improve-supply-1ff120e85d863311Pharma Surgeen2026-06-24T02:00:00.000ZPharmac funds another ADHD medicine to improve supplyhttps://www.pharmaradar360.com/article/new-agreement-to-save-hospitals-millions-2c2ea1d39fa2ac7ePharma Surgeen2026-06-24T02:00:00.000ZNew agreement to save hospitals millionshttps://www.pharmaradar360.com/article/otsuka-america-establishes-the-pocari-sweat-science-advisory-boardannounces-new-cdb07cd89e3d2a03Pharma Surgeen2026-06-24T01:00:00.000ZOtsuka America Establishes the POCARI SWEAT SCIENCE ADVISORY BOARDAnnounces New Heat Illness Prevention Guidance to Address Heat Challenges in the United Stateshttps://www.pharmaradar360.com/article/global-pharma-leadership-voices-the-future-of-pharmaceutical-innovation-begins-w-60ee3994fa4ec79fPharma Surgeen2026-06-24T00:40:00.000Z[Global Pharma Leadership Voices] The future of pharmaceutical innovation begins where patients still waithttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-40300354bf791c91Pharma Surgeen2026-06-24T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-47384458a63ba5f3Pharma Surgeen2026-06-24T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/new-treatment-option-recommended-for-recurrent-or-metastatic-cervical-cancer-eba35bc6e2bc0451Pharma Surgeen2026-06-24T00:00:00.000ZNew treatment option recommended for recurrent or metastatic cervical cancerhttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-06-24T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-90909cbf8abd046cPharma Surgeen2026-06-24T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-df0ec1fcc994385aPharma Surgeen2026-06-24T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-5c20e9aa3deaaa9dPharma Surgeen2026-06-24T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-5964c33eb4a2d83cPharma Surgeen2026-06-24T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-66103c9c2c23ce4bPharma Surgeen2026-06-24T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-fdc071a5910fc62ePharma Surgeen2026-06-24T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-b63a525872566d9dPharma Surgeen2026-06-24T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-50e088fb55c1d92bPharma Surgeen2026-06-24T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-39b49d88c0713289Pharma Surgeen2026-06-24T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d3d3923d09684c3cPharma Surgeen2026-06-24T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-58ba068f161a4c9fPharma Surgeen2026-06-24T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-da37ac21ff995968Pharma Surgeen2026-06-24T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-48c9a6ebde6323aePharma Surgeen2026-06-24T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-912f21e7f2affe4ePharma Surgeen2026-06-24T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-893712ea7fe33d49Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Chickens-Gallus Gallus; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-9bef3f045ec8bb7bPharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Felines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-4b2127e4ff8aa50ePharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Canines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-583c826a02c7beafPharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Porcines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-cae154bf8e2386e6Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Equines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-600224bd5b51ad56Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Caprines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-54092ff28d3b41e9Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Ovines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-25780f641f4d8a04Pharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Bovines; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/international-cooperation-on-harmonisation-of-technical-requirements-for-registr-31a2c3e7954c060ePharma Surgeen2026-06-24T00:00:00.000ZInternational Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: General Recommendations; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/medicare-and-state-health-care-programs-fraud-and-abuse-request-for-information-947a786c40a2498cPharma Surgeen2026-06-24T00:00:00.000ZMedicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Federal Anti-Kickback Statute and Beneficiary Inducements CMPhttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-temporary-placement-of-o-desmethyltramadol-in-4520029496532faePharma Surgeen2026-06-24T00:00:00.000ZSchedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule Ihttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-bromazolam-in-schedule-i-correct-e44a3995822493b1Pharma Surgeen2026-06-24T00:00:00.000ZSchedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correctionhttps://www.pharmaradar360.com/article/amanda-ward-n-d-decision-and-order-e801daf927427c9aPharma Surgeen2026-06-24T00:00:00.000ZAmanda Ward, N.D.; Decision and Orderhttps://www.pharmaradar360.com/article/irina-gross-d-p-m-decision-and-order-74c76b404fcf3298Pharma Surgeen2026-06-24T00:00:00.000ZIrina Gross, D.P.M.; Decision and Orderhttps://www.pharmaradar360.com/article/fiscal-year-fy-2026-notice-of-supplemental-funding-opportunity-963d21b3c27713dePharma Surgeen2026-06-24T00:00:00.000ZFiscal Year (FY) 2026 Notice of Supplemental Funding Opportunityhttps://www.pharmaradar360.com/article/demonstrating-substantial-evidence-of-effectiveness-for-human-drug-and-biologica-08058812b8eab8c7Pharma Surgeen2026-06-24T00:00:00.000ZDemonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/expedited-investigational-new-drug-pilot-program-request-for-information-d835e05efeee33d7Pharma Surgeen2026-06-24T00:00:00.000ZExpedited Investigational New Drug Pilot Program; Request for Informationhttps://www.pharmaradar360.com/article/master-protocols-for-drug-and-biological-product-development-draft-guidance-for-1fe1f9759aa3f262Pharma Surgeen2026-06-24T00:00:00.000ZMaster Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/quantitative-systems-pharmacology-qsp-based-dose-selection-for-minimum-anticipat-b46e928ff4245d85Pharma Surgeen2026-06-24T00:00:00.000ZQuantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/office-of-the-director-national-institutes-of-health-notice-of-closed-meeting-1a544af7d7fe2ed5Pharma Surgeen2026-06-24T00:00:00.000ZOffice of the Director, National Institutes of Health; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/cleveland-clinic-completes-its-first-robotic-lung-transplant-in-u-s-a1562a09eb2cf3c2Pharma Surgeen2026-06-24T00:00:00.000ZCleveland Clinic Completes Its First Robotic Lung Transplant in U.S.https://www.pharmaradar360.com/article/anesthesia-strategy-and-clinical-outcomes-in-ruptured-aortic-aneurysm-repair-ins-1d6639903b916616Pharma Surgeen2026-06-24T00:00:00.000ZAnesthesia Strategy and Clinical Outcomes in Ruptured Aortic Aneurysm Repair: Insights from EVAR and TEVARhttps://www.pharmaradar360.com/article/multi-target-mechanism-of-action-of-curcumin-in-rheumatoid-arthritis-and-clinica-60acd8593ec02f49Pharma Surgeen2026-06-24T00:00:00.000ZMulti-target Mechanism of Action of Curcumin in Rheumatoid Arthritis and Clinical Applicationhttps://www.pharmaradar360.com/article/role-of-tumor-markers-and-cytokines-in-the-pathogenesis-of-lung-cancer-ce787bcfbc03f090Pharma Surgeen2026-06-24T00:00:00.000ZRole of tumor markers and cytokines in the pathogenesis of lung cancerhttps://www.pharmaradar360.com/article/prominent-crosstalks-between-perineural-invasion-and-immunosuppressive-tumor-mic-afe5af6ada1b347fPharma Surgeen2026-06-24T00:00:00.000ZProminent crosstalks between perineural invasion and immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinomahttps://www.pharmaradar360.com/article/radiation-induced-cardiotoxicity-in-lung-cancer-current-landscape-and-future-dir-d87c06d8e2adf7d6Pharma Surgeen2026-06-24T00:00:00.000ZRadiation-induced cardiotoxicity in lung cancer: Current landscape and future directionshttps://www.pharmaradar360.com/article/letter-to-the-editor-yin-yang-1-in-inflammatory-memory-and-progression-susceptib-5055a860a59d8d08Pharma Surgeen2026-06-24T00:00:00.000ZLetter to the Editor: Yin Yang 1 in inflammatory memory and progression susceptibility in <i>Helicobacter pylori</i> –associated gastric cancerhttps://www.pharmaradar360.com/article/myo-inositol-and-d-chiro-inositol-in-polycystic-ovary-syndrome-mechanisms-of-act-da773c4ee911c586Pharma Surgeen2026-06-24T00:00:00.000ZMYO-INOSITOL AND D-CHIRO-INOSITOL IN POLYCYSTIC OVARY SYNDROME: MECHANISMS OF ACTION, CLINICAL EFFECTIVENESS, SAFETY, AND CURRENT LIMITATIONS: A NARRATIVE REVIEWhttps://www.pharmaradar360.com/article/effect-of-minimizing-light-exposure-with-digital-visualization-on-macular-functi-f8f9bc8f3ccfad66Pharma Surgeen2026-06-24T00:00:00.000ZEffect of Minimizing Light Exposure with Digital Visualization on Macular Function After Cataract Surgery in Patients with AMD: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-evaluation-of-a-combined-deep-learning-reconstructed-readout-segmented-467bf16bdca5a1b8Pharma Surgeen2026-06-24T00:00:00.000ZClinical Evaluation of a Combined Deep Learning–Reconstructed Readout-Segmented Echo-Planar Imaging and Water-Excitation Spectral Fat-Saturation Protocol for Breast Diffusion-Weighted Imaging at 3T Breast MRIhttps://www.pharmaradar360.com/article/promoting-physical-activity-and-reducing-sedentary-behavior-in-adults-with-type-e84257bf2f8ecbb7Pharma Surgeen2026-06-24T00:00:00.000ZPromoting Physical Activity and Reducing Sedentary Behavior in Adults with Type 2 Diabetes: Study Protocol of the DIA/01 Randomized Trialhttps://www.pharmaradar360.com/article/drug-repurposing-of-sophoridine-for-sepsis-induced-organ-injury-from-in-depth-an-4bcd17ca73223be2Pharma Surgeen2026-06-24T00:00:00.000ZDrug repurposing of sophoridine for sepsis-induced organ injury: from in-depth analysis of a single agent to a multi-target therapeutic paradigmhttps://www.pharmaradar360.com/article/methodologies-for-generating-and-evaluating-clinical-and-performance-evidence-fo-ef640109401d5054Pharma Surgeen2026-06-24T00:00:00.000ZMethodologies for generating and evaluating clinical and performance evidence for high-risk and innovative medical devices and in vitro diagnostics: a scoping reviewhttps://www.pharmaradar360.com/article/bridging-the-theory-practice-gap-in-laboratory-medicine-development-and-applicat-b0c7f3f0f1e62cd1Pharma Surgeen2026-06-24T00:00:00.000ZBridging the theory-practice gap in laboratory medicine: development and application of a standardized case library for fostering clinical reasoning in postgraduate traininghttps://www.pharmaradar360.com/article/fd571a746e1226d9Pharma Surgeen2026-06-24T00:00:00.000ZГіперімуноглобулінемія Е як причина тяжкого хронічного інфекційного ураження шкіри: клінічний випадокhttps://www.pharmaradar360.com/article/bea11ce3a6d7af0aPharma Surgeen2026-06-24T00:00:00.000ZДезлоратадин у сучасній системі пероральної доставки ліків: вартий вибір для належного лікування алергічних захворюваньhttps://www.pharmaradar360.com/article/high-concordance-in-molecular-profiles-between-primary-tumors-and-matched-lymph-d9efdb0ab1933651Pharma Surgeen2026-06-24T00:00:00.000ZHigh Concordance in Molecular Profiles Between Primary Tumors and Matched Lymph Node Metastases in Differentiated Thyroid Carcinoma: Implications for Clinical Sample Selectionhttps://www.pharmaradar360.com/article/immune-related-liver-injury-clinical-and-histological-subtyping-defines-distinct-643442e1a8d0cf98Pharma Surgeen2026-06-24T00:00:00.000ZImmune-related liver injury: Clinical and histological subtyping defines distinct trajectories and therapeutic implicationshttps://www.pharmaradar360.com/article/clinical-outcomes-of-6-fr-vs-8-fr-catheters-in-percutaneous-transhepatic-gallbla-aee4660af5453f30Pharma Surgeen2026-06-24T00:00:00.000ZClinical Outcomes of 6-Fr vs 8-Fr Catheters in Percutaneous Transhepatic Gallbladder Drainage: A Propensity Score-Matched Analysishttps://www.pharmaradar360.com/article/integrating-creative-and-community-health-services-into-clinical-workstreams-a-q-23202270067b574fPharma Surgeen2026-06-24T00:00:00.000ZIntegrating Creative and Community Health Services into Clinical Workstreams: A Qualitative Case Study from Gloucestershire Integrated Care Boardhttps://www.pharmaradar360.com/article/genomic-characterization-of-the-first-near-complete-goat-associated-orf-virus-ge-14d0cfee7040ef92Pharma Surgeen2026-06-24T00:00:00.000ZGenomic characterization of the first near-complete goat-associated Orf virus genome sequenced directly from a human clinical sample in Portugalhttps://www.pharmaradar360.com/article/predictors-of-achieving-remission-in-rheumatoid-arthritis-during-levilimab-thera-fa99a26b1e400d79Pharma Surgeen2026-06-24T00:00:00.000ZPredictors of achieving remission in rheumatoid arthritis during levilimab therapy in real-world clinical practicehttps://www.pharmaradar360.com/article/lupus-nephritis-in-patients-from-kyrgyzstan-clinical-and-laboratory-manifestatio-23e8bc4d1c06f8b1Pharma Surgeen2026-06-24T00:00:00.000ZLupus nephritis in patients from Kyrgyzstan: clinical and laboratory manifestations, disease course variants, and prognostic factors for developmenthttps://www.pharmaradar360.com/article/prospective-evaluation-of-the-effect-of-stopping-estrogen-containing-contracepti-f16ae0b12c1bc94ePharma Surgeen2026-06-24T00:00:00.000ZProspective evaluation of the effect of stopping estrogen-containing contraceptives on serum CBG and cortisol levelshttps://www.pharmaradar360.com/article/does-metabolically-healthy-obesity-really-exist-going-toward-new-definitions-d96a5263e512ff66Pharma Surgeen2026-06-24T00:00:00.000ZDoes Metabolically Healthy Obesity Really Exist: Going Toward New Definitionshttps://www.pharmaradar360.com/article/deciphering-the-role-of-adipose-tissue-microbial-dna-in-obesity-related-metaboli-256959ccde3d7740Pharma Surgeen2026-06-24T00:00:00.000ZDeciphering the role of adipose tissue microbial DNA in obesity-related metabolic dysfunctionhttps://www.pharmaradar360.com/article/speech-evoked-auditory-brainstem-response-as-a-biomarker-of-auditory-plasticity-dfc1df4d72aef704Pharma Surgeen2026-06-24T00:00:00.000ZSpeech-evoked auditory brainstem response as a biomarker of auditory plasticity: clinical and neurophysiological perspectives — a narrative reviewhttps://www.pharmaradar360.com/article/how-glycemic-variability-trajectories-impact-clinical-outcomes-in-critically-ill-bf8cff916ec6365bPharma Surgeen2026-06-24T00:00:00.000ZHow glycemic variability trajectories impact clinical outcomes in critically ill patients with severe pneumonia: a prospective cohort studyhttps://www.pharmaradar360.com/article/a-systematic-review-on-clinical-and-laboratory-effects-of-vitamin-d-deficiency-i-7fc645e307063ee6Pharma Surgeen2026-06-24T00:00:00.000ZA systematic review on clinical and laboratory effects of vitamin D deficiency in children with sickle cell diseasehttps://www.pharmaradar360.com/article/a-pragmatic-smart-study-of-medication-and-cbt-sequencing-in-pediatric-anxiety-di-d661ffd8150d9693Pharma Surgeen2026-06-24T00:00:00.000ZA Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/update-in-diagnosis-and-management-of-glucocorticoid-induced-osteoporosis-1b858c1a935e43a0Pharma Surgeen2026-06-24T00:00:00.000ZUpdate in Diagnosis and Management of Glucocorticoid-Induced Osteoporosishttps://www.pharmaradar360.com/article/roles-and-responsibilities-of-nutrition-nurses-276776f212b8275cPharma Surgeen2026-06-24T00:00:00.000ZRoles and Responsibilities of Nutrition Nurseshttps://www.pharmaradar360.com/article/periprocedural-cooling-during-botulinum-toxin-injection-surface-temperature-effe-fd9899277cccc93dPharma Surgeen2026-06-24T00:00:00.000ZPeriprocedural Cooling During Botulinum Toxin Injection: Surface Temperature Effects and Practical Clinical Considerationshttps://www.pharmaradar360.com/article/a-conversation-with-malcolm-willett-cartoonist-who-looks-at-us-with-a-wry-smile-808ddde23a1a2047Pharma Surgeen2026-06-24T00:00:00.000ZA Conversation With ... Malcolm Willett, Cartoonist Who Looks at Us With a Wry Smilehttps://www.pharmaradar360.com/article/real-world-recurrence-free-and-distant-metastasis-free-survival-in-early-stage-m-7ea54ece45e9f036Pharma Surgeen2026-06-24T00:00:00.000ZReal-world recurrence-free and distant metastasis-free survival in early-stage melanoma: concordance with KEYNOTE-716 trial estimateshttps://www.pharmaradar360.com/article/closing-the-gap-between-trial-and-clinical-reality-in-long-term-lvad-use-outcome-3b197dae38aa5a95Pharma Surgeen2026-06-24T00:00:00.000ZClosing the Gap Between Trial and Clinical Reality in Long-term LVAD Use Outcomeshttps://www.pharmaradar360.com/article/a-multi-centre-real-world-evaluation-of-ritlecitinib-in-severe-alopecia-areata-e-7374fdb196c99c80Pharma Surgeen2026-06-24T00:00:00.000ZA Multi-Centre Real-World Evaluation of Ritlecitinib in Severe Alopecia Areata: Early Real World Experience in a British Cohorthttps://www.pharmaradar360.com/article/a-review-of-male-genital-psoriasis-cbb089bbaba85d3bPharma Surgeen2026-06-24T00:00:00.000ZA Review of Male Genital Psoriasishttps://www.pharmaradar360.com/article/a-novel-drug-screening-strategy-based-on-non-invasive-electrochemical-detection-70c5f534dbc7cb98Pharma Surgeen2026-06-24T00:00:00.000ZA novel drug screening strategy based on non-invasive electrochemical detection of multiple tumor markers secreted by patient-derived microgel organoidshttps://www.pharmaradar360.com/article/neurobiomarker-guided-neuromodulation-for-youth-with-major-depressive-episodes-a-c7b9886c42124586Pharma Surgeen2026-06-24T00:00:00.000ZNeurobiomarker-guided neuromodulation for youth with major depressive episodes: a double-blind randomized trialhttps://www.pharmaradar360.com/article/from-breadth-to-depth-in-clinical-artificial-intelligence-evaluation-3dd8d26301e31542Pharma Surgeen2026-06-24T00:00:00.000ZFrom breadth to depth in clinical artificial intelligence evaluationhttps://www.pharmaradar360.com/article/retraction-note-carbon-nano-onion-mediated-dual-targeting-of-p-selectin-and-p-gl-7c5d9f5978a9c44dPharma Surgeen2026-06-24T00:00:00.000ZRetraction Note: Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistancehttps://www.pharmaradar360.com/article/efficacy-and-safety-of-hydrolyzed-collagen-supplementation-on-skin-health-outcom-71c73d71796e8e90Pharma Surgeen2026-06-24T00:00:00.000ZEfficacy and safety of hydrolyzed collagen supplementation on skin health outcomes: a systematic literature review of randomized controlled trialshttps://www.pharmaradar360.com/article/aprepitant-s-neuroprotective-effects-on-methylphenidate-induced-biochemical-mito-e3bd11b8177cb3daPharma Surgeen2026-06-24T00:00:00.000ZAprepitant’s neuroprotective effects on methylphenidate-induced biochemical/mitochondrial dysfunction, neuroinflammation, and mood-related behavior alterationshttps://www.pharmaradar360.com/article/mechanistic-insights-into-lgals3-mediated-osteoarthritis-progression-activation-a50ce0658f97c300Pharma Surgeen2026-06-24T00:00:00.000ZMechanistic Insights into LGALS3-Mediated Osteoarthritis Progression: Activation of the cGAS-STING Pathway as a Key Driver of Senescence-Related Osteoarthritishttps://www.pharmaradar360.com/article/multiparametric-characterization-of-tough-clots-following-stroke-thrombectomy-7c15a6a06bfaaeb7Pharma Surgeen2026-06-24T00:00:00.000ZMultiparametric Characterization of Tough Clots Following Stroke Thrombectomyhttps://www.pharmaradar360.com/article/protected-time-for-clinical-investigators-in-medical-oncology-the-persistent-gap-34ed88200a00aeccPharma Surgeen2026-06-24T00:00:00.000Z“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and realityhttps://www.pharmaradar360.com/article/nct07666477-rtms-and-olfactory-training-for-parkinson-s-disease-2d9e625a7fd75695Pharma Surgeen2026-06-24T00:00:00.000ZNCT07666477: rTMS and Olfactory Training for Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct07665762-liposomal-bupivacaine-plus-plain-bupivacaine-versus-dexamethasone-pl-b54eae4f5d8a9cf8Pharma Surgeen2026-06-24T00:00:00.000ZNCT07665762: Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Painhttps://www.pharmaradar360.com/article/nct07665268-study-title-a-multicenter-prospective-modified-platform-trial-evalua-c1fd2f936e55ebb7Pharma Surgeen2026-06-24T00:00:00.000ZNCT07665268: Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.https://www.pharmaradar360.com/article/nct07664644-hybrid-type-1-trial-of-a-parent-based-intervention-addressing-social-fa62e3a48a304fdePharma Surgeen2026-06-24T00:00:00.000ZNCT07664644: Hybrid Type 1 Trial of a Parent-Based Intervention Addressing Social Media and Adolescent Alcohol Usehttps://www.pharmaradar360.com/article/nct07659197-usefulness-of-the-vexus-protocol-for-dry-weight-adjustment-in-hemodi-3f5f697713a406d8Pharma Surgeen2026-06-24T00:00:00.000ZNCT07659197: Usefulness of the VExUS Protocol for Dry-Weight Adjustment in Hemodialysis Patients: The Multicenter VExHD Studyhttps://www.pharmaradar360.com/article/nct07574541-multitargeted-recombinant-ad5-psa-muc-1-brachyury-based-immunotherap-0f3af0b930fedd23Pharma Surgeen2026-06-24T00:00:00.000ZNCT07574541: Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillancehttps://www.pharmaradar360.com/article/nct07553715-effectiveness-of-a-four-session-focal-shock-wave-therapy-protocol-in-27d9f5701f4a3944Pharma Surgeen2026-06-24T00:00:00.000ZNCT07553715: Effectiveness of a Four-Session Focal Shock Wave Therapy Protocol in Women With Vulvodyniahttps://www.pharmaradar360.com/article/nct07504601-investigating-the-analgesic-potential-of-2r-6r-hnk-in-acute-pain-in-7d802ea0b5cc5a4ePharma Surgeen2026-06-24T00:00:00.000ZNCT07504601: Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteershttps://www.pharmaradar360.com/article/nct07496697-effects-of-electroacupuncture-at-np82-and-sp15-on-bowel-motility-in-e08cce00fbeedbcbPharma Surgeen2026-06-24T00:00:00.000ZNCT07496697: Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjectshttps://www.pharmaradar360.com/article/nct07419490-utero-ovarian-transposition-in-patients-with-pelvic-malignancies-und-eaa604e094303fbaPharma Surgeen2026-06-24T00:00:00.000ZNCT07419490: Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapyhttps://www.pharmaradar360.com/article/nct07407920-ph2-study-for-optimization-of-adjunct-systemic-therapy-in-her2-patie-e65d32bac992007cPharma Surgeen2026-06-24T00:00:00.000ZNCT07407920: Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trialhttps://www.pharmaradar360.com/article/nct07388550-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-po-c8883fe8549f9913Pharma Surgeen2026-06-24T00:00:00.000ZNCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)https://www.pharmaradar360.com/article/nct07376486-duodenal-pulsendo-as-an-early-treatment-for-type-2-dm-696e471c4ea757c2Pharma Surgeen2026-06-24T00:00:00.000ZNCT07376486: Duodenal pulsENDO as an Early Treatment for Type 2 DMhttps://www.pharmaradar360.com/article/nct07206589-minimally-invasive-approaches-for-the-diagnosis-of-barrett-s-esophag-a4f2e502b1c834c3Pharma Surgeen2026-06-24T00:00:00.000ZNCT07206589: Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trialhttps://www.pharmaradar360.com/article/nct07193550-a-phase-2-trial-of-zanzalintinib-in-advanced-metastatic-bone-sarcoma-6c0eeb636a2257d4Pharma Surgeen2026-06-24T00:00:00.000ZNCT07193550: A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)https://www.pharmaradar360.com/article/nct07009171-study-to-evaluate-the-efficacy-and-safety-of-kds2010-in-overweight-o-421574426b7091e0Pharma Surgeen2026-06-24T00:00:00.000ZNCT07009171: Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patientshttps://www.pharmaradar360.com/article/nct06991751-a-natural-history-of-cardiometabolic-disease-among-us-bhutanese-deve-74080274b3baf1daPharma Surgeen2026-06-24T00:00:00.000ZNCT06991751: A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...https://www.pharmaradar360.com/article/nct06952010-a-study-of-xb628-alone-and-in-combination-with-zanzalintinib-in-part-3fbb9d7ba2f6b40fPharma Surgeen2026-06-24T00:00:00.000ZNCT06952010: A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumorshttps://www.pharmaradar360.com/article/nct06892548-a-clinical-study-to-investigate-the-efficacy-and-safety-of-an-invest-b64dff0083f3b90bPharma Surgeen2026-06-24T00:00:00.000ZNCT06892548: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancerhttps://www.pharmaradar360.com/article/nct06673628-pembrolizumab-plus-lenvatinib-in-unresectable-cutaneous-angiosarcoma-5d87e06bf7c32b64Pharma Surgeen2026-06-24T00:00:00.000ZNCT06673628: Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patientshttps://www.pharmaradar360.com/article/nct06663319-a-study-of-jnj-89402638-for-metastatic-colorectal-and-gastric-cancer-a287e7e323b9bee8Pharma Surgeen2026-06-24T00:00:00.000ZNCT06663319: A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancershttps://www.pharmaradar360.com/article/nct06661122-a-study-to-learn-about-how-safe-darolutamide-is-and-how-well-it-work-aa536ef3c6be6b86Pharma Surgeen2026-06-24T00:00:00.000ZNCT06661122: A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancerhttps://www.pharmaradar360.com/article/nct06595953-gaze-contingent-music-therapy-augmentation-of-cbt-for-pediatric-anxi-e5479d1c7ad534d1Pharma Surgeen2026-06-24T00:00:00.000ZNCT06595953: Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxietyhttps://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2Pharma Surgeen2026-06-24T00:00:00.000ZNCT06595940: Genetic Analysis of Uncommon Disease Presentations in Non-US Populationshttps://www.pharmaradar360.com/article/nct06238622-a-follow-up-study-to-test-long-term-treatment-with-nerandomilast-in-e72e64c82219f942Pharma Surgeen2026-06-24T00:00:00.000ZNCT06238622: A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilasthttps://www.pharmaradar360.com/article/nct06200155-psilocybin-assisted-psychotherapy-in-patients-with-advanced-cancer-o-0d46d0afc351195aPharma Surgeen2026-06-24T00:00:00.000ZNCT06200155: Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapyhttps://www.pharmaradar360.com/article/nct05831085-diabetes-centered-evaluation-of-revascularization-strategy-of-functi-2e29bba552be8b4aPharma Surgeen2026-06-24T00:00:00.000ZNCT05831085: Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Diseasehttps://www.pharmaradar360.com/article/nct05621291-a-study-to-evaluate-next-generation-sequencing-ngs-testing-and-monit-b35317055f480c6ePharma Surgeen2026-06-24T00:00:00.000ZNCT05621291: A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...https://www.pharmaradar360.com/article/nct05519553-peer-support-impact-on-therapeutic-adherence-in-patients-with-multip-b955cafc7f3ebb92Pharma Surgeen2026-06-24T00:00:00.000ZNCT05519553: Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosishttps://www.pharmaradar360.com/article/nct05280548-a-study-to-evaluate-the-effect-of-venglustat-tablets-on-left-ventric-dcbe9ed093cb6c9fPharma Surgeen2026-06-24T00:00:00.000ZNCT05280548: A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Diseasehttps://www.pharmaradar360.com/article/nct04570423-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-eflapegrastim-d885f05b286ca878Pharma Surgeen2026-06-24T00:00:00.000ZNCT04570423: A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapyhttps://www.pharmaradar360.com/article/nct04323540-treatment-of-peri-implantitis-with-or-without-simultaneous-soft-tiss-ef3f9b50f60e5624Pharma Surgeen2026-06-24T00:00:00.000ZNCT04323540: Treatment of Peri-implantitis With or Without Simultaneous Soft Tissue Augmentationhttps://www.pharmaradar360.com/article/nct04067219-skin-muscle-and-bone-aging-determinants-in-hiv-infected-patients-b323bb50be55cfc3Pharma Surgeen2026-06-24T00:00:00.000ZNCT04067219: SkIn, Muscle and Bone Aging Determinants in HIV Infected-patients.https://www.pharmaradar360.com/article/nct03841617-the-use-of-124-i-pet-ct-whole-body-and-lesional-dosimetry-in-differe-f411f274236149c9Pharma Surgeen2026-06-24T00:00:00.000ZNCT03841617: The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancerhttps://www.pharmaradar360.com/article/nct02858323-complement-c1q-binding-to-hla-antibodies-in-a-solid-phase-immunoassa-aac53cbd7fa52c42Pharma Surgeen2026-06-24T00:00:00.000ZNCT02858323: Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet Transfusionhttps://www.pharmaradar360.com/article/nct01989572-sargramostim-vaccine-therapy-or-sargramostim-and-vaccine-therapy-in-8073ee76463b7312Pharma Surgeen2026-06-24T00:00:00.000ZNCT01989572: Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgeryhttps://www.pharmaradar360.com/article/nct01575548-pazopanib-hydrochloride-in-treating-patients-with-metastatic-kidney-946b03d7bdce5a61Pharma Surgeen2026-06-24T00:00:00.000ZNCT01575548: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgeryhttps://www.pharmaradar360.com/article/nct01352949-stereophotogrammetry-of-the-torso-in-healthy-individuals-and-patient-56494f162af5547cPharma Surgeen2026-06-24T00:00:00.000ZNCT01352949: Stereophotogrammetry of the Torso in Healthy Individuals and Patients With Scoliosis, Chest Wall Deformations, or Obesityhttps://www.pharmaradar360.com/article/nct00678821-aerobic-exercise-in-patients-with-pulmonary-hypertension-90751c87a327975dPharma Surgeen2026-06-24T00:00:00.000ZNCT00678821: Aerobic Exercise in Patients With Pulmonary Hypertensionhttps://www.pharmaradar360.com/article/nct00344331-evaluation-of-biochemical-markers-and-clinical-investigation-of-niem-46b02e456052464bPharma Surgeen2026-06-24T00:00:00.000ZNCT00344331: Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type Chttps://www.pharmaradar360.com/article/nvidia-bets-on-agentic-ai-to-turbocharge-biotech-discovery-e1bab1612da854bfPharma Surgeen2026-06-23T23:52:28.000ZNvidia bets on agentic AI to turbocharge biotech discoveryhttps://www.pharmaradar360.com/article/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy-83e7b78763dfa4ddPharma Surgeen2026-06-23T23:34:53.000ZLilly, Astellas circle Sangamo assets as biotech files for bankruptcyhttps://www.pharmaradar360.com/article/european-commission-approves-padcevtm-enfortumab-vedotin-in-combination-with-key-cb0f40e00c75fc97Pharma Surgeen2026-06-23T23:30:00.000ZEuropean Commission Approves PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) as the First and Only Approved Perioperative Treatment Option for Cisplatin-Ineligible Patients with Resectable Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/china-s-biotech-boom-record-5-215-clinical-drug-trials-reported-in-2025-512cbe9901526da7Pharma Surgeen2026-06-23T23:00:06.000ZChina’s biotech boom: record 5,215 clinical drug trials reported in 2025https://www.pharmaradar360.com/article/key-takeaways-leveraging-china-s-biotech-ecosystem-62b2ecb59640e3fbPharma Surgeen2026-06-23T22:01:09.000ZKey Takeaways | Leveraging China’s biotech ecosystemhttps://www.pharmaradar360.com/article/diet-pill-death-triggers-raids-525083a8d1d6f840Pharma Surgeen2026-06-23T21:19:00.000ZDiet pill death triggers raidshttps://www.pharmaradar360.com/article/base-editing-biotech-launches-straight-onto-nasdaq-in-reverse-merger-with-boundl-5e82d191d061890ePharma Surgeen2026-06-23T21:14:34.000ZBase-editing biotech launches straight onto NASDAQ in reverse merger with Boundlesshttps://www.pharmaradar360.com/article/reuters-health-news-summary-c58b743718a880a1Pharma Surgeen2026-06-23T21:00:10.000ZReuters Health News Summaryhttps://www.pharmaradar360.com/article/biotech-blues-the-not-so-hidden-costs-of-prior-art-lessons-in-pharma-and-psyched-b27b52402293421aPharma Surgeen2026-06-23T20:37:54.000ZBiotech Blues & The Not-So-Hidden Costs of Prior Art: Lessons in Pharma and Psychedelicshttps://www.pharmaradar360.com/article/biotech-etfs-gain-momentum-via-ai-drug-discovery-surging-m-a-29c0578045a88b45Pharma Surgeen2026-06-23T20:29:09.000ZBiotech ETFs Gain Momentum via AI Drug Discovery & Surging M&Ahttps://www.pharmaradar360.com/article/biotech-s-silent-resurgence-5-year-base-breakout-0a3973d729d9754cPharma Surgeen2026-06-23T20:17:00.000ZBiotech's Silent Resurgence (5-Year Base Breakout)https://www.pharmaradar360.com/article/chlorthalidone-blood-pressure-drug-recalled-nationwide-after-fda-warning-925654448d9a3225Pharma Surgeen2026-06-23T20:15:57.000ZChlorthalidone Blood Pressure Drug Recalled Nationwide After FDA Warninghttps://www.pharmaradar360.com/article/fda-pilot-targets-faster-early-stage-drug-trial-starts-pharmexec-d9707c6b7d603b7ePharma Surgeen2026-06-23T20:12:58.000ZFDA Pilot Targets Faster Early-Stage Drug Trial Starts | PharmExechttps://www.pharmaradar360.com/article/revolution-medicines-rvmd-initiates-phase-3-trial-for-pancreatic-cancer-treatmen-b4b4adf8de6f4390Pharma Surgeen2026-06-23T20:11:10.000ZRevolution Medicines (RVMD) Initiates Phase 3 Trial for Pancreatic Cancer Treatmenthttps://www.pharmaradar360.com/article/retail-investors-say-don-t-miss-this-top-biotech-stock-with-huge-upside-potentia-b1e76638783de56ePharma Surgeen2026-06-23T19:56:45.000ZRetail Investors Say Don’t Miss This Top Biotech Stock With Huge Upside Potentialhttps://www.pharmaradar360.com/article/bio-2026-nvidia-announces-the-bionemo-toolkit-for-ai-agents-648fcc1746f19184Pharma Surgeen2026-06-23T19:41:15.000ZBIO 2026: NVIDIA announces the BioNeMo toolkit for AI agentshttps://www.pharmaradar360.com/article/sen-gillibrand-raises-concerns-about-china-s-ability-to-attract-u-s-biotech-inve-a4c2670ff0be8275Pharma Surgeen2026-06-23T19:25:23.000ZSen. Gillibrand Raises Concerns About China’s Ability To Attract U.S. Biotech Investment, Partnershttps://www.pharmaradar360.com/article/exclusive-pro-life-groups-press-todd-blanche-to-settle-fda-mail-in-abortion-pill-630936c463b45f64Pharma Surgeen2026-06-23T18:53:56.000ZExclusive | Pro-life groups press Todd Blanche to settle FDA mail-in abortion pill case: ‘Unborn children are killed’https://www.pharmaradar360.com/article/haisco-licenses-two-drug-candidates-to-nuvectis-for-40m-upfront-by-investing-com-104f0663e2b14366Pharma Surgeen2026-06-23T18:41:32.000ZHaisco licenses two drug candidates to Nuvectis for $40m upfront By Investing.comhttps://www.pharmaradar360.com/article/pharmaceutical-trade-group-files-lawsuits-to-block-state-laws-on-pbms-c1d14cfac9dd77dfPharma Surgeen2026-06-23T18:38:28.000ZPharmaceutical Trade Group Files Lawsuits to Block State Laws on PBMshttps://www.pharmaradar360.com/article/discreet-biotech-osanni-bio-starts-making-noise-with-190m-series-b-for-clinical-ec5b4d05223060d7Pharma Surgeen2026-06-23T18:28:07.000ZDiscreet biotech Osanni Bio starts making noise with $190M series B for clinical pushhttps://www.pharmaradar360.com/article/serapha-bio-takes-flight-from-boundless-merger-with-230m-and-gene-editing-prospe-a7454d1e9469cc1ePharma Surgeen2026-06-23T17:55:35.000ZSerapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from Chinahttps://www.pharmaradar360.com/article/fda-changes-rare-disease-tune-again-as-it-clears-path-for-regenxbio-s-gene-thera-774399748468386ePharma Surgeen2026-06-23T17:46:37.000ZFDA changes rare disease tune again as it clears path for Regenxbio’s gene therapyhttps://www.pharmaradar360.com/article/update-lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy-8324c3daefbe6634Pharma Surgeen2026-06-23T17:35:00.000ZUPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcyhttps://www.pharmaradar360.com/article/pro-life-doctors-urge-fda-to-reinstate-abortion-pill-safeguards-ecf30141dc812a34Pharma Surgeen2026-06-23T16:50:00.000ZPro-Life Doctors Urge FDA to Reinstate Abortion Pill Safeguardshttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-verrica-stock-rating-on-trial-progress-bddc8e6cc081c74bPharma Surgeen2026-06-23T16:47:43.000ZH.C. Wainwright reiterates Verrica stock rating on trial progresshttps://www.pharmaradar360.com/article/apifix-46d2d81a536c4a0fPharma Surgeen2026-06-23T16:28:37.000ZApiFix®https://www.pharmaradar360.com/article/u-s-global-health-legislation-tracker-ec916851cb08fd5cPharma Surgeen2026-06-23T16:27:00.000ZU.S. Global Health Legislation Trackerhttps://www.pharmaradar360.com/article/certara-launches-bio-venture-catalyst-for-emerging-biotechs-to-de-risk-investmen-285e38daf51b4e87Pharma Surgeen2026-06-23T16:23:54.000ZCertara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Developmenthttps://www.pharmaradar360.com/article/sanofi-multiple-sclerosis-drug-gets-eu-approval-despite-fda-letter-sanofi-nasdaq-3e896f367a324190Pharma Surgeen2026-06-23T16:21:34.000ZSanofi Multiple Sclerosis Drug Gets EU Approval Despite FDA Letter - Sanofi (NASDAQ:SNY)https://www.pharmaradar360.com/article/integrating-endogenous-ligand-competition-into-a-mechanistic-whole-body-pbpk-mod-dc624ab93f1623c5Pharma Surgeen2026-06-23T16:01:47.000ZIntegrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodieshttps://www.pharmaradar360.com/article/urgent-public-health-messages-0fe32b0d2989273fPharma Surgeen2026-06-23T16:00:19.000ZUrgent public health messageshttps://www.pharmaradar360.com/article/personal-protective-equipment-and-heat-risk-of-heat-stress-4e57439b6595dceaPharma Surgeen2026-06-23T16:00:00.000ZPersonal protective equipment and heat: risk of heat stresshttps://www.pharmaradar360.com/article/uld-container-vs-non-uld-container-what-is-the-difference-1d6f91f02d1e259fPharma Surgeen2026-06-23T15:40:56.000ZULD Container vs.Non-ULD Container: What Is the Difference?https://www.pharmaradar360.com/article/63-runs-and-no-convergence-when-rsnlme-succeeded-where-others-couldn-t-e3c26a63c947bf74Pharma Surgeen2026-06-23T15:40:06.000Z63 Runs and No Convergence: When RsNLME Succeeded Where Others Couldn’thttps://www.pharmaradar360.com/article/cordis-project-european-african-vaccine-initiative-eavi-accelerating-preventive-450f5665b25341fdPharma Surgeen2026-06-23T15:36:12.000ZCORDIS project: EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB-SAHARAN AFRICAhttps://www.pharmaradar360.com/article/cordis-project-spatial-crosstalk-in-immuno-oncology-125d828393882e8dPharma Surgeen2026-06-23T15:33:43.000ZCORDIS project: Spatial Crosstalk in Immuno-Oncologyhttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-27-report-data-to-week-26-data-up-t-39d0cd44b81694a0Pharma Surgeen2026-06-23T15:32:44.000ZNational norovirus and rotavirus report, week 27 report: data to week 26 (data up to 28 June 2026)https://www.pharmaradar360.com/article/witness-carolina-s-role-in-the-revolutionary-war-950bffcb032a61c8Pharma Surgeen2026-06-23T15:31:34.000Z‘Witness’ Carolina’s role in the Revolutionary Warhttps://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-9354f373822a4db7Pharma Surgeen2026-06-23T15:30:38.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, May 2025 to May 2026https://www.pharmaradar360.com/article/ns-035-ad3fe6ba9e021a37Pharma Surgeen2026-06-23T15:30:00.000Z福山型先天性筋ジストロフィー治療剤「NS-035」希少疾病用医薬品指定のお知らせhttps://www.pharmaradar360.com/article/64eecea013c8434fPharma Surgeen2026-06-23T15:30:00.000Zボストン小児病院との共同研究契約締結のお知らせhttps://www.pharmaradar360.com/article/the-first-90-days-after-fda-clearance-greenlight-guru-4dbaf47997c9ea77Pharma Surgeen2026-06-23T15:26:40.000ZThe first 90 days after FDA clearance | Greenlight Guruhttps://www.pharmaradar360.com/article/cordis-project-next-generation-toolbox-for-greener-pharmaceuticals-design-manufa-54347cb6058aea6aPharma Surgeen2026-06-23T15:23:36.000ZCORDIS project: Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impacthttps://www.pharmaradar360.com/article/field-safety-notices-15-to-19-june-2026-0dae56725b81dbb3Pharma Surgeen2026-06-23T15:23:17.000ZField Safety Notices: 15 to 19 June 2026https://www.pharmaradar360.com/article/reforming-the-general-medical-council-legislative-framework-d5e8f0967636328aPharma Surgeen2026-06-23T15:17:27.000ZReforming the General Medical Council legislative frameworkhttps://www.pharmaradar360.com/article/the-tea-in-your-kombucha-changes-more-than-just-the-taste-922ed75d23508a0bPharma Surgeen2026-06-23T15:06:00.000ZThe tea in your kombucha changes more than just the tastehttps://www.pharmaradar360.com/article/la-unlp-realizara-una-jornada-de-asesoramiento-previsional-0d92d5ca55059efaPharma Surgeen2026-06-23T15:05:43.000ZLa UNLP realizará una jornada de asesoramiento previsionalhttps://www.pharmaradar360.com/article/nueva-entrega-de-computadoras-a-estudiantes-de-la-unlp-f5fac08c2fd2a85dPharma Surgeen2026-06-23T15:05:06.000ZNueva entrega de computadoras a estudiantes de la UNLPhttps://www.pharmaradar360.com/article/fda-clears-investigational-new-drug-application-for-remyelinating-agent-ptd802-i-fe8f227bc03ebcc2Pharma Surgeen2026-06-23T15:00:36.000ZFDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosishttps://www.pharmaradar360.com/article/huella-hidrica-c1ca10512b51cc09Pharma Surgeen2026-06-23T14:59:24.000ZHuella hídricahttps://www.pharmaradar360.com/article/palabras-del-presidente-fernando-tauber-en-el-inicio-de-su-gestion-2026-2030-9a9dbd51e9b55d1dPharma Surgeen2026-06-23T14:57:40.000ZPalabras del Presidente Fernando Tauber en el inicio de su gestión 2026-2030https://www.pharmaradar360.com/article/pittsburgh-business-leader-to-head-2026-heart-walk-and-citywide-push-for-cpr-rea-916f5884ac4bd6a2Pharma Surgeen2026-06-23T14:57:00.000ZPittsburgh business leader to head 2026 Heart Walk and citywide push for CPR readinesshttps://www.pharmaradar360.com/article/jornada-de-buen-trato-hacia-las-personas-mayores-db8a1513d3e95feaPharma Surgeen2026-06-23T14:55:25.000ZJornada de buen trato hacia las personas mayoreshttps://www.pharmaradar360.com/article/pfizer-lung-cancer-drug-misses-key-survival-goal-in-phase-3-trial-8b3d1bf2adcc60eaPharma Surgeen2026-06-23T14:39:57.000ZPfizer lung cancer drug misses key survival goal in Phase 3 trialhttps://www.pharmaradar360.com/article/adult-social-care-data-collection-september-2025-notice-9f4a973804b186c3Pharma Surgeen2026-06-23T14:39:42.000ZAdult social care data collection: September 2025 noticehttps://www.pharmaradar360.com/article/pfizer-lung-cancer-drug-sigvotatug-vedotin-fails-phase-3-trial-887a8d9f613040c8Pharma Surgeen2026-06-23T14:39:12.000ZPfizer lung cancer drug sigvotatug vedotin fails phase 3 trialhttps://www.pharmaradar360.com/article/cpa-da-ufrj-define-coordenacao-e-planeja-proximos-passos-da-avaliacao-institucio-8f80df7fa0acbbefPharma Surgeen2026-06-23T14:35:00.000ZCPA da UFRJ define coordenação e planeja próximos passos da avaliação institucionalhttps://www.pharmaradar360.com/article/scientists-finally-solved-how-h5n1-bird-flu-hid-in-dairy-cows-0bc6afc35a6a5a50Pharma Surgeen2026-06-23T14:31:51.000ZScientists finally solved how H5N1 bird flu hid in dairy cowshttps://www.pharmaradar360.com/article/performance-of-the-techcyte-ai-based-image-analysis-system-for-coproparasitologi-f52fee6ab651e077Pharma Surgeen2026-06-23T14:23:29.000ZPerformance of the Techcyte AI-based image analysis system for coproparasitological diagnosis in clinical stool specimens: a retrospective evaluation studyhttps://www.pharmaradar360.com/article/the-fortin-family-foundation-makes-extraordinary-5-million-gift-to-the-campaign-ca842f128560900bPharma Surgeen2026-06-23T14:23:07.000ZThe Fortin Family Foundation Makes Extraordinary $5 Million Gift to the Campaign for St. Vincent Regional Hospitalhttps://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7Pharma Surgeen2026-06-23T14:17:25.000ZMedicines eligible for Northern Ireland MHRA Authorised Routehttps://www.pharmaradar360.com/article/merck-kgaa-pledges-50m-to-new-biotech-with-eye-to-acquisition-0c97d126c0f31953Pharma Surgeen2026-06-23T14:16:26.000ZMerck KGaA pledges $50M to new biotech with eye to acquisitionhttps://www.pharmaradar360.com/article/las-invasiones-inglesas-y-el-nacimiento-de-una-identidad-nacional-5ff061e1aeaee733Pharma Surgeen2026-06-23T14:08:13.000ZLas Invasiones Inglesas y el nacimiento de una identidad nacionalhttps://www.pharmaradar360.com/article/pfizer-pfe-lung-cancer-drug-misses-survival-goal-in-phase-3-trial-0c7871d67c93cf30Pharma Surgeen2026-06-23T14:06:26.000ZPfizer (PFE) Lung Cancer Drug Misses Survival Goal In Phase 3 Trialhttps://www.pharmaradar360.com/article/ananda-pharma-confirms-safety-of-cbd-drug-as-clinical-pain-trials-approach-c665f71802097e49Pharma Surgeen2026-06-23T14:05:57.000ZAnanda Pharma Confirms Safety of CBD Drug, as Clinical Pain Trials Approachhttps://www.pharmaradar360.com/article/homenaje-a-la-bandera-en-los-jardines-del-rectorado-df0d43f386ffd1cbPharma Surgeen2026-06-23T13:59:59.000ZHomenaje a la Bandera en los jardines del Rectoradohttps://www.pharmaradar360.com/article/application-of-io-simulator-in-immuno-oncology-combination-therapy-a-small-cell-3d00c4089200d552Pharma Surgeen2026-06-23T13:58:37.000ZApplication of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Studyhttps://www.pharmaradar360.com/article/breve-elogio-sobre-la-libertad-academica-b735fca67b2a4d6cPharma Surgeen2026-06-23T13:57:55.000ZBreve elogio sobre la libertad académicahttps://www.pharmaradar360.com/article/the-medical-frailty-exemption-from-medicaid-work-requirements-key-takeaways-from-60411ed4c27b4044Pharma Surgeen2026-06-23T13:55:48.000ZThe Medical Frailty Exemption from Medicaid Work Requirements: Key Takeaways from the CMS Interim Final Rulehttps://www.pharmaradar360.com/article/fourteen-oxford-academics-awarded-major-european-research-council-advanced-grant-6f61084b1c8139d5Pharma Surgeen2026-06-23T13:53:43.000ZFourteen Oxford academics awarded major European Research Council Advanced Grantshttps://www.pharmaradar360.com/article/strategic-health-purchasing-as-an-enabler-of-health-systems-resilience-in-fragil-87d57da5ee7b76eePharma Surgeen2026-06-23T13:47:24.000ZStrategic Health Purchasing as an Enabler of Health Systems Resilience in Fragile States: Evidence from South Sudanhttps://www.pharmaradar360.com/article/fortitude-and-heartsciences-nasdaq-hscs-announce-business-combination-aiming-to-3980f5efadd81bc3Pharma Surgeen2026-06-23T13:44:56.000ZFortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Marketshttps://www.pharmaradar360.com/article/mas-sustentable-la-unlp-redujo-un-12-su-huella-de-carbono-dc3615e7287227ecPharma Surgeen2026-06-23T13:44:30.000ZMás sustentable: la UNLP redujo un 12% su huella de carbonohttps://www.pharmaradar360.com/article/la-unlp-reunio-a-mas-de-40-equipos-editoriales-en-el-encuentro-de-revistas-cient-ac9de3f9fd2728c9Pharma Surgeen2026-06-23T13:43:52.000ZLa UNLP reunió a más de 40 equipos editoriales en el Encuentro de Revistas Científicashttps://www.pharmaradar360.com/article/jornada-por-el-dia-mundial-del-ambiente-accion-por-el-clima-del-saber-al-hacer-37181135bcdc5ec7Pharma Surgeen2026-06-23T13:43:10.000ZJornada por el día mundial del ambiente: acción por el clima, del saber al hacerhttps://www.pharmaradar360.com/article/la-unlp-realizo-una-nueva-colecta-de-sangre-y-jornada-integral-de-salud-fe045f3184c5898bPharma Surgeen2026-06-23T13:42:30.000ZLa UNLP realizó una nueva colecta de sangre y jornada integral de saludhttps://www.pharmaradar360.com/article/haisco-enters-into-exclusive-license-agreement-with-nuvectis-for-two-drug-candid-fa80a162db5f40f7Pharma Surgeen2026-06-23T13:41:30.000ZHaisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indicationshttps://www.pharmaradar360.com/article/agenda-conjunta-con-la-union-de-parlamentarios-sudamericanos-764a255dfc8902b0Pharma Surgeen2026-06-23T13:38:16.000ZAgenda conjunta con la Unión de Parlamentarios Sudamericanoshttps://www.pharmaradar360.com/article/tauber-recorrio-las-obras-del-edificio-anexo-de-derecho-80e838733cabaa73Pharma Surgeen2026-06-23T13:36:36.000ZTauber recorrió las obras del edificio Anexo de Derechohttps://www.pharmaradar360.com/article/jornada-por-una-universidad-libre-de-humo-y-nicotina-5e6696bbbe94980fPharma Surgeen2026-06-23T13:34:02.000ZJornada por una Universidad libre de humo y nicotinahttps://www.pharmaradar360.com/article/la-unlp-y-china-afianzan-lazos-de-cooperacion-con-la-inauguracion-de-un-nuevo-ce-b656851b1493f8dcPharma Surgeen2026-06-23T13:33:25.000ZLa UNLP y China afianzan lazos de cooperación con la inauguración de un nuevo centro culturalhttps://www.pharmaradar360.com/article/measuring-the-pull-side-innovation-burden-for-pharmaceutical-drugs-by-oecd-count-99381439bf77007cPharma Surgeen2026-06-23T13:33:25.000ZMeasuring the Pull-Side Innovation Burden for Pharmaceutical Drugs by OECD Countryhttps://www.pharmaradar360.com/article/revolution-medicines-begins-phase-3-trial-for-pancreatic-cancer-15d1ae6150e07ef5Pharma Surgeen2026-06-23T13:31:31.000ZRevolution Medicines begins phase 3 trial for pancreatic cancerhttps://www.pharmaradar360.com/article/galectin-reaches-fda-agreement-on-phase-3-trial-for-belapectin-9afd3d197807afddPharma Surgeen2026-06-23T13:25:45.000ZGalectin reaches FDA agreement on Phase 3 trial for belapectinhttps://www.pharmaradar360.com/article/revolutionary-copd-injection-given-to-patients-for-first-time-261b7d9eb2567bdfPharma Surgeen2026-06-23T13:24:12.000ZRevolutionary COPD injection given to patients for first timehttps://www.pharmaradar360.com/article/what-makes-mri-the-perfect-fit-for-interventional-workflows-these-pioneers-expla-c83c049dc6a0954bPharma Surgeen2026-06-23T13:17:45.000ZWhat Makes MRI the Perfect Fit for Interventional Workflows? These Pioneers Explain.https://www.pharmaradar360.com/article/de-risk-adenoviral-vector-development-with-an-adaptive-platform-73e51507005b33eePharma Surgeen2026-06-23T13:10:00.000ZDe-Risk Adenoviral Vector Development with an Adaptive Platformhttps://www.pharmaradar360.com/article/sk-pharmteco-announces-skyvectm-a-unified-high-yield-viral-vector-platform-desig-fe7647be36171d83Pharma Surgeen2026-06-23T13:05:00.000ZSK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedsidehttps://www.pharmaradar360.com/article/mechanistic-modelling-of-crs-in-t-cell-engagers-an-application-for-blinatumomab-310fc062f187c580Pharma Surgeen2026-06-23T12:59:15.000ZMechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomabhttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-29776fbc92997ea0Pharma Surgeen2026-06-23T12:59:11.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: Related Resourceshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-da141fb5d19965f4Pharma Surgeen2026-06-23T12:59:06.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: 1115-waivershttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-38463bac8179533dPharma Surgeen2026-06-23T12:59:01.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Implementation Questionshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-6639d664866d5eddPharma Surgeen2026-06-23T12:58:56.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirementshttps://www.pharmaradar360.com/article/tracking-implementation-of-the-2025-reconciliation-law-medicaid-work-requirement-f066079fc0240f7ePharma Surgeen2026-06-23T12:58:10.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Data and Policieshttps://www.pharmaradar360.com/article/easygrid-towards-better-automation-in-cryo-electron-microscopy-3e5dc74d617e422dPharma Surgeen2026-06-23T12:39:38.000ZEasyGrid: towards better automation in cryo-electron microscopyhttps://www.pharmaradar360.com/article/fda-approval-of-semaglutide-for-weight-loss-spurs-surge-in-u-s-poison-control-ca-a6dd53fcdcfdf13aPharma Surgeen2026-06-23T12:34:30.000ZFDA Approval of Semaglutide for Weight Loss Spurs Surge in U.S. Poison Control Calls, UT San Antonio Study Findshttps://www.pharmaradar360.com/article/pfizer-delivers-disappointing-late-stage-lung-cancer-data-for-adc-from-43b-seage-5d299ffc93c517a3Pharma Surgeen2026-06-23T12:31:14.000ZPfizer delivers ‘disappointing’ late-stage lung cancer data for ADC from $43B Seagen buyhttps://www.pharmaradar360.com/article/medication-abortion-decisions-from-federal-courts-the-fda-or-trump-s-department-d38d4aa748308a24Pharma Surgeen2026-06-23T12:29:44.000ZMedication abortion: Decisions from federal courts, the FDA or Trump’s Department of Justice could try to end access via telehealthhttps://www.pharmaradar360.com/article/basic-science-research-retreat-aims-at-collaboration-2be2816482c0c999Pharma Surgeen2026-06-23T12:19:57.000ZBasic science research retreat aims at collaborationhttps://www.pharmaradar360.com/article/dr-erickson-to-take-new-continuing-education-role-f8e68238ad39ff4dPharma Surgeen2026-06-23T12:18:56.000ZDr. Erickson to take new continuing education rolehttps://www.pharmaradar360.com/article/regan-taylor-md-named-director-of-phase-2-7fa1c7f864285b93Pharma Surgeen2026-06-23T12:17:40.000ZRegan Taylor, MD, named director of Phase 2https://www.pharmaradar360.com/article/medical-research-highlights-june-2026-ee724de04515f5f0Pharma Surgeen2026-06-23T12:15:30.000ZMedical research highlights, June 2026https://www.pharmaradar360.com/article/mello-finishes-term-as-aamc-steering-committee-chair-7c68909bd57d0202Pharma Surgeen2026-06-23T12:14:05.000ZMello finishes term as AAMC steering committee chair